74 results
8-K
EX-99.2
ANNX
Annexon Inc
4 Jun 24
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
7:05am
State Severely Disabled of Health Disabled/Death 0-1: Good State of Health 0 1 2 3 4 5 6 2-3: Disabled 4-6: Severely Disabled/Death ANX005 Shift
8-K
EX-99.1
ANNX
Annexon Inc
4 Mar 24
Regulation FD Disclosure
5:25pm
conduction failure and nerve fiber death Global annual incidence ~150,000, lifetime likelihood of 1 in 1,000 PERIPHERAL NERVE DAMAGE LEADS TO: Severe weakness … risk for mechanical ventilation or death and prognosis Preceding infection PLATEAU PHASE: lasts weeks to months post-treatment Complete/ partial
8-K
EX-99.1
gblb3xn qi6qgaj
8 Jan 24
Regulation FD Disclosure
4:09pm
8-K
EX-99.1
e6urn8z0at
11 Oct 23
Annexon Announces Clinical and Regulatory Progress for ANX005 Pivotal
4:44pm
8-K
EX-99.2
mt2t gpby5lbsdxn
8 Jul 22
Annexon Announces $130 Million Private Placement Financing
5:19pm